Toxicity Management, Monitoring, and Quality-of-Life Concerns

Dr. Traina and the panel address the practical challenges of monitoring for toxicities, notably interstitial lung disease (ILD) with TDXd, as these therapies enter the curative setting. They discuss how protocol-driven frequent scans, vigilant symptom monitoring, and appropriate adjustment of drug schedules are critical for patient safety. Real-world strategies to apply intensive clinical trial monitoring to broader patient populations are debated, including the implications for concurrent therapies (such as radiation). The segment closes with a thoughtful consideration of how much toxicity is tolerable in curative-intent therapy versus metastatic settings.